Cytokine & Growth Factor Reviews最新文献_第2页

Molecular regulation of mitophagy signaling in tumor microenvironment and its targeting for cancer therapy.

IF 9.3 2区医学

Cytokine & Growth Factor Reviews Pub Date : 2025-01-17 DOI: 10.1016/j.cytogfr.2025.01.004

Bishnu Prasad Behera, Soumya Ranjan Mishra, Srimanta Patra, Kewal Kumar Mahapatra, Chandra Sekhar Bhol, Debasna Pritimanjari Panigrahi, Prakash Priyadarshi Praharaj, Daniel J Klionsky, Sujit Kumar Bhutia

{"title":"Molecular regulation of mitophagy signaling in tumor microenvironment and its targeting for cancer therapy.","authors":"Bishnu Prasad Behera, Soumya Ranjan Mishra, Srimanta Patra, Kewal Kumar Mahapatra, Chandra Sekhar Bhol, Debasna Pritimanjari Panigrahi, Prakash Priyadarshi Praharaj, Daniel J Klionsky, Sujit Kumar Bhutia","doi":"10.1016/j.cytogfr.2025.01.004","DOIUrl":"10.1016/j.cytogfr.2025.01.004","url":null,"abstract":"<p><p>Aberrations emerging in mitochondrial homeostasis are restrained by mitophagy to control mitochondrial integrity, bioenergetics signaling, metabolism, oxidative stress, and apoptosis. The mitophagy-accompanied mitochondrial processes that occur in a dysregulated condition act as drivers for cancer occurrence. In addition, the enigmatic nature of mitophagy in cancer cells modulates the cellular proteome, creating challenges for therapeutic interventions. Several reports found the role of cellular signaling pathways in cancer to modulate mitophagy to mitigate stress, immune checkpoints, energy demand, and cell death. Thus, targeting mitophagy to hinder oncogenic intracellular signaling by promoting apoptosis, in hindsight, might have an edge against cancer. This review highlights the receptors and adaptors, and the involvement of many proteins in mitophagy and their role in oncogenesis. It also provides insight into using mitophagy as a potential target for therapeutic intervention in various cancer types.</p>","PeriodicalId":11132,"journal":{"name":"Cytokine & Growth Factor Reviews","volume":" ","pages":""},"PeriodicalIF":9.3,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insights into IL-6/JAK/STAT3 signaling in the tumor microenvironment: Implications for cancer therapy.

IF 9.3 2区医学

Cytokine & Growth Factor Reviews Pub Date : 2025-01-17 DOI: 10.1016/j.cytogfr.2025.01.003

Win Lwin Thuya, Yang Cao, Paul Chi-Lui Ho, Andrea Li-Ann Wong, Lingzhi Wang, Jianbiao Zhou, Christophe Nicot, Boon Cher Goh

{"title":"Insights into IL-6/JAK/STAT3 signaling in the tumor microenvironment: Implications for cancer therapy.","authors":"Win Lwin Thuya, Yang Cao, Paul Chi-Lui Ho, Andrea Li-Ann Wong, Lingzhi Wang, Jianbiao Zhou, Christophe Nicot, Boon Cher Goh","doi":"10.1016/j.cytogfr.2025.01.003","DOIUrl":"https://doi.org/10.1016/j.cytogfr.2025.01.003","url":null,"abstract":"<p><p>The IL-6/JAK/STAT3 signaling pathway is a key regulator of tumor progression, immune evasion, and therapy resistance in various cancers. Frequently dysregulated in malignancies, this pathway drives cancer cell growth, survival, angiogenesis, and metastasis by altering the tumor microenvironment (TME). IL-6 activates JAK kinases and STAT3 through its receptor complex, leading to the transcription of oncogenic genes and fostering an immunosuppressive TME. This environment recruits tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), and regulatory T cells (Tregs), collectively supporting immune evasion and tumor growth. IL-6/JAK/STAT3 axis also contributes to metabolic reprogramming, such as enhanced glycolysis and glutathione metabolism, helping cancer cells adapt to environmental stresses. Therapeutic targeting of this pathway has gained significant interest. Strategies include monoclonal antibodies against IL-6 or its receptor (e.g., Tocilizumab, Siltuximab), JAK inhibitors (e.g., Ruxolitinib), and STAT3-specific inhibitors (e.g., Napabucasin), which have exhibited promise in preclinical and initial clinical studies. These inhibitors can suppress tumor growth, reverse immune suppression, and enhance the efficacy of immunotherapies like immune checkpoint inhibitors. Combination therapies that integrate IL-6 pathway inhibitors with conventional treatments are particularly promising, addressing resistance mechanisms and improving patient outcomes. Advances in biomarker-driven patient selection, RNA-based therapies, and isoform-specific inhibitors pave the way for more precise interventions. This review delves into the diverse roles of IL-6/JAK/STAT3 signaling in cancer progression, therapeutic strategies targeting this pathway, and the potential for integrating these approaches into personalized medicine to enhance treatment outcomes.</p>","PeriodicalId":11132,"journal":{"name":"Cytokine & Growth Factor Reviews","volume":" ","pages":""},"PeriodicalIF":9.3,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interleukin-6 (IL-6)-associated tumor microenvironment remodelling and cancer immunotherapy. 白细胞介素-6 （IL-6）相关的肿瘤微环境重塑和癌症免疫治疗。

IF 9.3 2区医学

Cytokine & Growth Factor Reviews Pub Date : 2025-01-10 DOI: 10.1016/j.cytogfr.2025.01.001

Songsong Wu, Zhumin Cao, Rongying Lu, Zhenwang Zhang, Gautam Sethi, Yulai You

{"title":"Interleukin-6 (IL-6)-associated tumor microenvironment remodelling and cancer immunotherapy.","authors":"Songsong Wu, Zhumin Cao, Rongying Lu, Zhenwang Zhang, Gautam Sethi, Yulai You","doi":"10.1016/j.cytogfr.2025.01.001","DOIUrl":"https://doi.org/10.1016/j.cytogfr.2025.01.001","url":null,"abstract":"<p><p>Interleukin-6 (IL-6) is a pro-inflammatory cytokine playing a pivotal role during inflammation and immune responses. In the recent years, the function of IL-6 in the tumor microenvironment (TME) for affecting tumorigenesis and immunotherapy response has been investigated. The genetic mutations are mainly responsible for the development of cancer, while interactions in TME are also important, involving both cancers and non-cancerous cells. IL-6 plays a significant role in these interactions, enhancing the proliferation, survival and metastasis of tumor cells through inflammatory pathways, highlighting its carcinogenic function. Multiple immune cells including macrophages, T cells, myeloid-derived suppressor cells, dendritic cells and natural killer cells can be affected by IL-6 to develop immunosuppressive TME. IL-6 can also participate in the immune evasion through increasing levels of PD-L1, compromising the efficacy of therapeutics. Notably, IL-6 exerts a double-edge sword function and it can dually increase or decrease cancer immunotherapy, providing a challenge for targeting this cytokine in cancer therapy. Highlighting the complicated function of IL-6 in TME can lead to the development of effective therapeutics for cancer immunity.</p>","PeriodicalId":11132,"journal":{"name":"Cytokine & Growth Factor Reviews","volume":" ","pages":""},"PeriodicalIF":9.3,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanisms coupling the mTOR pathway to chronic obstructive pulmonary disease (COPD) pathogenesis mTOR通路与慢性阻塞性肺疾病（COPD）发病机制的耦合

IF 9.3 2区医学

Cytokine & Growth Factor Reviews Pub Date : 2025-01-03 DOI: 10.1016/j.cytogfr.2024.12.005

Ankita Goyal , Vishal Chopra , Kranti Garg , Siddharth Sharma

{"title":"Mechanisms coupling the mTOR pathway to chronic obstructive pulmonary disease (COPD) pathogenesis","authors":"Ankita Goyal , Vishal Chopra , Kranti Garg , Siddharth Sharma","doi":"10.1016/j.cytogfr.2024.12.005","DOIUrl":"10.1016/j.cytogfr.2024.12.005","url":null,"abstract":"<div><div>Chronic Obstructive Pulmonary Disease (COPD) is a poorly reversible respiratory disorder distinguished by dyspnea, cough, expectoration and exacerbations due to abnormality of airways or emphysema. In this review, we consider the therapeutic potential of targeting Mammalian target of Rapamycin (mTOR) for treating COPD. The mTOR is a highly conserved serine-threonine protein kinase that integrates signals from growth factors and nutrients to control protein synthesis, lipid biogenesis and metabolism. Dysregulated mTOR pathway signaling due to genetic factors or cigarette smoking impairs autophagy, driving the buildup of abnormal cells and damaged proteins, resulting in inflammation and oxidative stress. Persistent mTOR activation also contributes to pulmonary vascular cell proliferation, facilitating the development of pulmonary resistance in COPD. Rapamycin, an inhibitor of mTOR, prevents the buildup of senescent cells in the lungs of COPD patients and inhibits the release of lung tissue-damaging proteases. mTOR also impacts the corticosteroid sensitivity in COPD patients by regulating the levels of histone deacetylases. The emerging role of gut-lung axis dysbiosis in the progression of COPD and its influence on mTOR further highlights the relevance of the mTOR pathway in COPD pathophysiology.</div></div>","PeriodicalId":11132,"journal":{"name":"Cytokine & Growth Factor Reviews","volume":"82 ","pages":"Pages 55-69"},"PeriodicalIF":9.3,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The immunopathogenesis of a cytokine storm: The key mechanisms underlying severe COVID-19

IF 9.3 2区医学

Cytokine & Growth Factor Reviews Pub Date : 2025-01-02 DOI: 10.1016/j.cytogfr.2024.12.003

Luka Hiti , Tijana Markovič , Mitja Lainscak , Jerneja Farkaš Lainščak , Emil Pal , Irena Mlinarič-Raščan

{"title":"The immunopathogenesis of a cytokine storm: The key mechanisms underlying severe COVID-19","authors":"Luka Hiti , Tijana Markovič , Mitja Lainscak , Jerneja Farkaš Lainščak , Emil Pal , Irena Mlinarič-Raščan","doi":"10.1016/j.cytogfr.2024.12.003","DOIUrl":"10.1016/j.cytogfr.2024.12.003","url":null,"abstract":"<div><div>A cytokine storm is marked by excessive pro-inflammatory cytokine release, and has emerged as a key factor in severe COVID-19 cases – making it a critical therapeutic target. However, its pathophysiology was poorly understood, which hindered effective treatment. SARS-CoV-2 initially disrupts angiotensin signalling, promoting inflammation through ACE-2 downregulation. Some patients’ immune systems then fail to shift from innate to adaptive immunity, suppressing interferon responses and leading to excessive pyroptosis and neutrophil activation. This amplifies tissue damage and inflammation, creating a pro-inflammatory loop. The result is the disruption of Th1/Th2 and Th17/Treg balances, lymphocyte exhaustion, and extensive blood clotting. Cytokine storm treatments include glucocorticoids to suppress the immune system, monoclonal antibodies to neutralize specific cytokines, and JAK inhibitors to block cytokine receptor signalling. However, the most effective treatment options for mitigating SARS-CoV-2 infection remain vaccines as a preventive measure and antiviral drugs for the early stages of infection. This article synthesizes insights into immune dysregulation in COVID-19, offering a framework to better understand cytokine storms and to improve monitoring, biomarker discovery, and treatment strategies for COVID-19 and other conditions involving cytokine storms.</div></div>","PeriodicalId":11132,"journal":{"name":"Cytokine & Growth Factor Reviews","volume":"82 ","pages":"Pages 1-17"},"PeriodicalIF":9.3,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ubiquitination in pyroptosis pathway: A potential therapeutic target for sepsis 热蛋白沉积途径中的泛素化：败血症的潜在治疗靶点

IF 9.3 2区医学

Cytokine & Growth Factor Reviews Pub Date : 2024-12-01 DOI: 10.1016/j.cytogfr.2024.09.001

Yan Liao , Wangzheqi Zhang , Miao Zhou , Chenglong Zhu , Zui Zou

引用次数: 0

Adeno-associated virus therapies: Pioneering solutions for human genetic diseases 腺相关病毒疗法：人类遗传疾病的开创性解决方案。

IF 9.3 2区医学

Cytokine & Growth Factor Reviews Pub Date : 2024-12-01 DOI: 10.1016/j.cytogfr.2024.09.003

Dequan Liu , Tian Li , Lei Liu , Xiangyu Che , Xiaorui Li , Chang Liu , Guangzhen Wu

引用次数: 0

Molecular mechanisms of regulation of IL-1 and its receptors 调节 IL-1 及其受体的分子机制。

IF 9.3 2区医学

Cytokine & Growth Factor Reviews Pub Date : 2024-12-01 DOI: 10.1016/j.cytogfr.2024.09.004

J.V. Zhukova , J.A. Lopatnikova , A.A. Alshevskaya , S.V. Sennikov

引用次数: 0

Mechanisms of Rho GTPases in regulating tumor proliferation, migration and invasion Rho GTPases 调节肿瘤增殖、迁移和侵袭的机制。

IF 9.3 2区医学

Cytokine & Growth Factor Reviews Pub Date : 2024-12-01 DOI: 10.1016/j.cytogfr.2024.09.002

Cheng Liu , Shutao Chen , Yu Zhang , Xinyi Zhou , Haiwei Wang , Qigui Wang , Xi Lan

引用次数: 0

Glioblastoma-associated macrophages: A key target in overcoming glioblastoma therapeutic resistance 胶质母细胞瘤相关巨噬细胞：克服胶质母细胞瘤耐药性的关键靶点

IF 9.3 2区医学

Cytokine & Growth Factor Reviews Pub Date : 2024-12-01 DOI: 10.1016/j.cytogfr.2024.10.009

Aymane Kricha, Najat Bouchmaa, Sanae Ben Mkaddem, Abdellatif Abbaoui, Reda Ben Mrid, Rachid El Fatimy

{"title":"Glioblastoma-associated macrophages: A key target in overcoming glioblastoma therapeutic resistance","authors":"Aymane Kricha, Najat Bouchmaa, Sanae Ben Mkaddem, Abdellatif Abbaoui, Reda Ben Mrid, Rachid El Fatimy","doi":"10.1016/j.cytogfr.2024.10.009","DOIUrl":"10.1016/j.cytogfr.2024.10.009","url":null,"abstract":"<div><div>Glioblastoma multiforme (GBM) is recognized as the most aggressive and malignant form of brain cancer, characterized by a highly heterogeneous phenotype, poor prognosis, and a median survival time of less than 16 months. Recent studies have highlighted the critical role of glioblastoma-associated macrophages (GAMs) in promoting tumor progression and resistance not only to immunotherapy but also to radiotherapy and chemotherapy. GAMs actively suppress immune responses, promote angiogenesis, facilitate tumor metastasis, and induce therapy resistance, through various mechanisms such as cytokines production, signaling pathways regulation, and angiogenesis. In this context, understanding these regulatory mechanisms is essential for developing efficient therapies. Preclinical studies have investigated diverse approaches to target these cells, both as monotherapies or in combination with other treatments. While these approaches have shown promise in strengthening antitumor immune responses in animal models, their clinical success remains to be fully determined. Herein, we provide a comprehensive overview of GAMs's role in GBM therapeutic resistance and summarizes existing approaches to target GAMs in overcoming tumor resistance.</div></div>","PeriodicalId":11132,"journal":{"name":"Cytokine & Growth Factor Reviews","volume":"80 ","pages":"Pages 97-108"},"PeriodicalIF":9.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0